Experimental neurology and state of preclinical research

Experimental Neurology

Volumn 239, Issue 1, 2013, Pages

  Hoke, Ahmet ^a,b  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL RESEARCH; EDITORIAL; EXPERIMENTAL STUDY; HUMAN; NEUROLOGIC DISEASE; NEUROLOGY; NEUROSCIENCE; PERIPHERAL NERVOUS SYSTEM; PRECLINICAL RESEARCH; PRIORITY JOURNAL; PUBLICATION; REPRODUCIBILITY; SCIENTIFIC LITERATURE;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; NERVOUS SYSTEM DISEASES; NEUROLOGY; PUBLISHING; RESEARCH;

EID: 84871837425     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2012.12.011     Document Type: Editorial

References (4)

1. Begley C.G., Ellis L.M. Drug development: raise standards for preclinical cancer research. Nature 2012, 483:531-533.
2. Peers I.S., Ceuppens P.R., Harbron C. In search of preclinical robustness. Nat. Rev. Drug Discov. 2012, 11:733-734.
3. Prinz F., Schlange T., Asadullah K. Believe it or not: how much can we rely on published data on potential drug targets?. Nat. Rev. Drug Discov. 2011, 10:712.
4. Windle W.F. Introduction. Exp. Neurol. 1959, 1:1.